规律使用磷酸二酯酶5抑制剂减少复发性缺血性阴茎异常勃起的急诊就诊
该回顾性研究评估规律使用磷酸二酯酶5抑制剂(PDE5i)对复发性缺血性阴茎异常勃起患者急诊就诊的影响。结果显示治疗期间每月急诊就诊次数减少4.4倍(p<0.001),勃起持续时间和频率分级均显著改善(p<0.001),92%患者报告改善,支持PDE5i作为预防策略。
要点
- 规律PDE5i治疗使复发性缺血性阴茎异常勃起患者每月急诊就诊减少4.4倍。
- 治疗期间阴茎异常勃起持续时间和频率分级均显著降低(p<0.001)。
核心结论
- 规律PDE5i治疗是管理复发性缺血性阴茎异常勃起的有效方法,客观和主观指标均改善。
- 本研究支持将规律PDE5i给药作为复发性缺血性阴茎异常勃起的预防策略。
研究设计与样本
- 回顾性病历审查,纳入2006年5月至2020年1月期间开始规律PDE5i治疗的复发性缺血性阴茎异常勃起患者。
- 共识别216例各种原因阴茎异常勃起患者,其中114例诊断为复发性缺血性阴茎异常勃起,42例开始规律PDE5i治疗,最终24例可评估疗效。
主要发现
- 治疗使每月急诊就诊次数减少4.4倍(p<0.001),阴茎异常勃起持续时间分级(p<0.001)和频率分级(p<0.001)均显著改善。
- 24例患者中22例(92%)报告阴茎异常勃起结局改善,其中9例报告复发性缺血性阴茎异常勃起发作缓解。
- 17例停药后复发的患者亚组分析显示,停药后阴茎异常勃起持续时间(p<0.001)和频率(p<0.001)显著增加,但每月急诊就诊次数无显著变化(p=0.91)。
关键数值与推荐
- 24例可评估患者中,病因特发性12例(50%)、镰状细胞病11例(46%)、药物诱发1例(4%)。
- 规律PDE5i使用中位时长为3个月(IQR 2-7)。
临床怎么用
- 对于复发性缺血性阴茎异常勃起患者,可考虑规律使用PDE5i作为预防性治疗以减少急诊就诊和发作频率。
局限性
- 回顾性研究设计,样本量较小(24例可评估),可能存在选择偏倚和信息偏倚。
- 停药后亚组分析中急诊就诊次数无显著变化,需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the real-world effectiveness of regimented phosphodiesterase type 5 inhibitor dosing on recurrent ischemic priapism outcomes using emergency department visits as a proxy for therapeutic control of the disorder. MATERIALS AND METHODS: We performed a retrospective chart review of patients with recurrent ischemic priapism who were started on regimented phosphodiesterase type 5 inhibitor therapy from May 2006 to January 2020. We compared the number of emergency department visits per month during a 6-month period before treatment, during treatment and after treatment discontinuation. We extracted and categorized priapism outcomes such as priapism frequency and duration. RESULTS: Of 216 patients identified with all cause priapism 114 were diagnosed with recurrent ischemic priapism and 42 were initiated on regimented phosphodiesterase type 5 inhibitor therapy. Treatment effectiveness was analyzed for 24 evaluable patients. Priapism etiology was idiopathic in 12 patients (50%), sickle cell disease in 11 (46%) and drug-induced in 1 (4%). The median length of regimented phosphodiesterase type 5 inhibitor use was 3 months (IQR 2-7). Treatment decreased emergency department visits per month by 4.4-fold (p <0.001), priapism duration tiers (p <0.001) and priapism frequency tiers (p <0.001). Of 24 patients 22 (92%) reported improvement in priapism outcomes, 9 of whom reported resolution of recurrent ischemic priapism episodes. A subgroup analysis of 17 patients with recurrent ischemic priapism relapse after treatment discontinuation showed a significant increase in priapism duration (p <0.001) and frequency (p <0.001) but no significant change in emergency department visits per month (p=0.91). CONCLUSIONS: Regimented phosphodiesterase type 5 inhibitor therapy was an impactful treatment in managing recurrent ischemic priapism according to objective and subjective parameters. This study provides further support for the use of regimented phosphodiesterase type 5 inhibitor dosing as a preventive strategy for recurrent ischemic priapism.
引用
- Hou LT, Burnett AL. Regimented Phosphodiesterase Type 5 Inhibitor Use Reduces Emergency Department Visits for Recurrent Ischemic Priapism. J Urol. 2020. PMID: 32915079. doi:10.1097/JU.0000000000001365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。